<DOC>
	<DOCNO>NCT02840539</DOCNO>
	<brief_summary>The purpose study determine whether bortezomib , cytarabine , dexamethasone effective treatment relapse refractory mantle cell lymphoma 1 3 line previous treatment .</brief_summary>
	<brief_title>Trial Bortezomib , Cytarabine , Dexamethasone Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Pathologically confirm mantle cell lymphoma Relapse progression 13 line previous chemotherapy without immunologic agent ECOG performance status 2 less Adequate hematologic , hepatic , renal function . White blood cell ≥ 3,000 /ul ii . Absolute neutrophil count ≥ 1,000 /ul iii . Platelets ≥ 50,000 /ul iv . Hemoglobin ≥ 9.0 g/dL v. Total bilirubin &lt; 2 time upper limit normal vi . AST , ALT &lt; 2.5 time upper limit normal vii . Serum creatinine &lt; 1.5 time upper limit normal Previously treat 4 line chemotherapy without immunologic agent Previously treat bortezomib Treated cytarabinecontaining regimen last line within 6 month registration Other cancer diagnose within 5 year registration Uncontrolled symptomatic CNS involvement mantle cell lymphoma Uncontrolled systemic infection Inherited immunodeficiency disease AIDS Pregnancy Breastfeeding Peripheral neuropathy grade 3 high Other health condition consider inappropriate trial primary physician 's opinion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Mantle cell lymphoma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Cytarabine</keyword>
</DOC>